Articles On Compumedics (ASX:CMP)

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

 Clinuvel chairman tells restless investors the company is on track despite share price weakness Opthea to front prestigious New York investment conference Compumedics is back in black as it tackles the sleep home-testing market   Alive a...

Wall Street had mixed results; but focus turns to tonight’s US jobs report Nvidia and Tesla saw gains; Broadcom fell 7pc on weak forecast Why investors are very jittery about tonight’s US jobs report   The ASX is expected to tick up modes...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

Sleep is essential for wellbeing but often overlooked in healthy habits Compumedics designs and manufactures technologies for the diagnosis of sleep disorders  TrivarX is focused on the theory that sleep is the window into mental health wi...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

ASX 200 punches it, record highs back in view  11 of 11 sectors higher, like a well-oiled machine  Great day for small caps, goldies and Augustus Minerals Local markets surged this morning after yet another record-breaking night for Wa...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

The ASX took a slow dive to a 50-point slump before a weak post-lunch rally Big gains for some big coal players were basically the only thing keeping us afloat A handful of Small Caps did pretty well, but it’s not been great day overall  ...

Aussie shares rally Rate sensitive stocks gain, led by Tech FTL soars on Newfoundland deal   Aussie shares climbed strongly on Thursday closing above 7,820 as major global central banks began to cut interest rates and in the US, the S&amp...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Echo IQ is awaiting FDA approval for its AI-powered EchoSolv platform EchoSolv utilises machine learning algorithms to detect aortic stenosis Stockhead reached out to Echo IQ’s COO, Deon Strydom   When looking at a healthcare stock to buy...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Momentum investing has been shown to be a successful strategy over the long term. The strategy essentially involves “buying high, but hoping to sell even higher” – which is the counter to the well known strategy of “buy low and sell high”....

A momentum trader will essentially be “buying high, but hoping to sell even higher” – which is the counter to the well known strategy of “buy low and sell high”. The biggest question for momentum traders is therefore how to find those stock...

The ASX benchmark has closed slightly lower on Friday Losses across the Energy Sector weighed Small caps led ID8   The Aussie sharemarket has ended lower on Friday, driven to a small disgrace by the ongoing declines in oil prices – down...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

The ASX has ended Wednesday jumping almost 100 points. Huge effort, everyone Energy Sector misses out on all the positive vibes Small caps led by Findi and Firebrick Pharma   The Australian sharemarket is in fine fettle on this Wednesday...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Benchmark slides throughout the day after a shocker on Wall Street last night. Utilities did best but still ended up losing, down 0.3% for the day. Paincheck a ray of sunshine this afternoon, up 33% today despite an early speeding ticket....

The ASX 200 benchmark falls 0.6% as we brace for news from The Fed Sector losses led by Resources, while Consumers make gains Small caps led by Alderan, and BNPL Sezzle returns   Local markets made it a hat trick of losses, with the re...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week   Earlier this week, Pfizer surprised the market by say...

The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit   Medicare, telehealth and mental...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

ASX 200 down 0.41% on lower than normal volume  Small cap index falls 1.17% and 7 out 11 sectors finish lower RBA raises the cash rate by 25 basis points to 3%   The ASX200 was down 0.41% today. The ASX Emerging Companies (XEC) index was...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

US inflation is at the highest level in 41 years Wall Street was down, but didn’t react strongly to the data The ASX is set to open flattish US CPI delivered another shock as the latest release showed that headline inflation rose by 9.1%...

The ASX 200 ends ever so slightly up, XEC finds 0.4% Gains in consumer discretionary, tech offset big losses for energy, resources, materials. South Korea, Kiwi’s lift rates ahead of tonight’s US CPI read Investors are facing crunch time...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Both ASX Small Cap and benchmark index are down about 0.5% A bleak forecast from Covid-stricken China hits resources stocks Appen in trading halt after jumping 30%     Local markets took a turn for the worse on Thursday after Chinese Prem...

Aussie small cap index falls flat, day two The ASX200 up 0.65% Conico is 50% higher   Rising gold prices and teetering tech stocks are playing dice for the soul of the ASX Emerging Companies (XEC) index on Wednesday, as the small cap top...